CRT
Cross Timbers Royalty Trust·Energy
10.40
1.701%(−0.18)
Market ClosedLast Updated: — ET
52W L: $7.0752W H: $11.46
CRT NEWS
defenseworld.net
Mar 29
Cross Timbers Royalty Trust (NYSE:CRT) Major Shareholder Eric Oliver Buys 3,159 Shares of Stock
Cross Timbers Royalty Trust (NYSE: CRT - Get Free Report) major shareholder Eric Oliver purchased 3,159 shares of the stock in a transaction that occurred on Thursday, March 26th. The stock was bought at an average cost of $9.91 per share, for a total transaction of $31,305.69. Following the acquisition, the insider directly owned 629,384 shares
defenseworld.net
Mar 28
Insider Buying: Cross Timbers Royalty Trust (NYSE:CRT) Major Shareholder Acquires 26,134 Shares of Stock
Cross Timbers Royalty Trust (NYSE: CRT - Get Free Report) major shareholder Eric Oliver bought 26,134 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were purchased at an average cost of $9.69 per share, for a total transaction of $253,238.46. Following the acquisition, the insider directly owned 626,225
prnewswire.com
Mar 20
CROSS TIMBERS ROYALTY TRUSTDECLARES MARCH CASH DISTRIBUTION
DALLAS, March 20, 2026 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust (the "Trust") (NYSE: CRT), today declared a cash distribution to the holders of its units of beneficial interest of $0.000923 per unit, payable on April 14, 2026, to unitholders of record on March 31, 2026. The following table shows underlying oil and gas sales and average prices attributable to the current month and prior month distributions.
seekingalpha.com
Mar 5
CT REIT: Expect More Dividend Increases
CT Real Estate Investment Trust offers a 5.5% yield, supported by robust AFFO growth and a conservative payout ratio. Over 90% of CRT.UN's rent comes from Canadian Tire under triple net leases, aligning interests and providing stable cash flows. Retained AFFO fully funds a C$330 million development pipeline, supporting continued low single-digit AFFO and distribution growth through the decade.
globenewswire.com
Mar 5
Autonomix Medical Selected for Best Innovation Competition at CRT 2026
THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its presentation titled, “Illuminating The Nervous System With Transvascular Precision-guided Technology,” has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026.
globenewswire.com
Mar 4
Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC.
